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Differential Regulatory Role of
Pituitary Adenylate Cyclase–Activating Polypeptide
in the Serum-Transfer Arthritis Model
Ba´lint Botz,1 Kata Bölcskei,1 La´szlo´ Kereskai,2 Miklo´s Kova´cs,3 Tama´s Ne´meth,3
Krisztia´n Szigeti,4 Ildiko´ Horva´th,4 Domokos Ma´the´,5 Noe´mi Kova´cs,6 Hitoshi Hashimoto,7
Do´ra Reglo˝di,8 Ja´nos Szolcsa´nyi,9 Erika Pinte´r,1 Attila Mo´csai,3 and Zsuzsanna Helyes1
Objective. Pituitary adenylate cyclase–activating
polypeptide (PACAP) expressed in capsaicin-sensitive
sensory neurons and immune cells has divergent func-
tions in inflammatory and pain processes. This study
was undertaken to investigate the involvement of
PACAP in a mouse model of rheumatoid arthritis.
Methods. Arthritis was induced in PACAP/ and
wild-type (PACAP/) mice by K/BxN serum transfer.
General features of the disease were investigated by
semiquantitative scoring, plethysmometry, and histo-
pathologic analysis. Mechano- and thermonociceptive
thresholds and motor functions were also evaluated.
Metabolic activity was assessed by positron emission
tomography. Bone morphology was measured by in vivo
micro–computed tomography, myeloperoxidase activity
and superoxide production by bioluminescence imaging
with luminol and lucigenin, respectively, and vascular
permeability by fluorescent indocyanine green dye
study.
Results. PACAP/ mice developed notable joint
swelling, reduced grasping ability, and mechanical (but
not thermal) hyperalgesia after K/BxN serum transfer.
In PACAP/ mice clinical scores and edema were
significantly reduced, and mechanical hyperalgesia and
motor impairment were absent, throughout the 2-week
period of observation. Metabolic activity and superoxide
production increased in the tibiotarsal joints of wild-
type mice but were significantly lower in PACAP/
animals. Myeloperoxidase activity in the ankle joints of
PACAP/ mice was significantly reduced in the early
phase of arthritis, but increased in the late phase.
Synovial hyperplasia was also significantly increased,
and progressive bone spur formation was observed in
PACAP-deficient mice only.
Conclusion. In PACAP-deficient mice with serum-
transfer arthritis, joint swelling, vascular leakage, hyper-
algesia, and early inflammatory cell accumulation are
reduced; in the later phase of the disease, immune cell
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function and bone neoformation are increased. Elucida-
tion of the underlying pathways of PACAP activity may
open promising new avenues for development of therapy
in inflammatory arthritis.
Rheumatoid arthritis (RA) is a common inflam-
matory joint disorder that may severely impair quality of
life due to chronic, persistent pain and functional loss. In
the early phase it is characterized by edema and tender-
ness around the affected joints, which are later accom-
panied by progressive, irreversible degeneration and
bone remodeling. Immunologic factors that are predom-
inantly involved in the inflammatory components of RA
have been well described. In contrast, the mechanisms of
chronic pain and sensitization, as well as the complexity
of neurovascular and neuroimmune interactions, have
received much less study, although the importance of
neurogenic inflammation in the pathophysiologic pro-
cesses of RA was described long ago (1). The relatively
recent availability of biologic therapies has considerably
improved the treatment of RA, but early intervention
and identification of novel drug targets are imperative to
prevent the disease from progressing to the less man-
ageable late phase (2,3).
Pituitary adenylate cyclase–activating polypep-
tide (PACAP) belongs to the vasoactive intestinal poly-
peptide (VIP)/secretin/glucagon family (4). It is present
in 27– and 38–amino acid–containing forms, the latter
being predominant in most mammalian tissues. Its 3 G
protein–coupled receptors (GPCRs) can be activated by
both forms: PAC1 is specific for PACAP, whereas
VPAC1 and VPAC2 are activated by both VIP and
PACAP (5). In the last decade it was discovered that
PACAP-27 also activates formyl peptide receptor–like 1
(FPRL1), a rhodopsin-like GPCR (6). Activation of the
PAC1 receptor results in cAMP production, inositol
trisphosphate turnover, increased intracellular calcium
levels and phospholipase D activity. VPAC1/VPAC2
receptor activation induces primarily cAMP production
(7).
PACAP is widely expressed in the nervous system
(e.g., the brain, the superficial layer of the spinal dorsal
horn, and capsaicin-sensitive sensory neurons) (7). It
regulates nociceptive transmission in a complex manner:
it is antihyperalgesic in several peripheral processes, but
mainly pronociceptive centrally. Therefore, PACAP has
been suggested to play a crucial role in central sensiti-
zation and the induction of chronic pain (7–9). We have
provided evidence that peripherally administered
PACAP-38 is antinociceptive in several models of acute
pain, but induces sensitization of the knee joint primary
afferents (10). It has been postulated that it activates
VPAC1/VPAC2 receptors located on nociceptive nerve
terminals within the articular capsule, thus increasing
joint hypersensitivity similarly to VIP, which exerts its
pronociceptive effect in osteoarthritis through the same
pathway (11). PACAP has a potent vasodilatory effect
through the PAC1 receptor and facilitates plasma leak-
age, edema formation, and leukocyte migration (12,13).
We have also shown that PACAP has a crucial role in
the long-term maintenance of neurogenic vasodilation
on the periphery (14).
The role of PACAP in inflammation and immu-
noregulation has been studied extensively, and it has
been suggested to be an important endogenous immu-
nomodulator (7). Its receptors are widely distributed in
the immune system: PAC1 is expressed on macrophages
and monocytes, but not on lymphocytes (15). VPAC1 is
present on both T and B lymphocytes, macrophages, and
monocytes, whereas the VPAC2 receptor is expressed
only on stimulated lymphocytes and macrophages (16).
The FPRL1 receptor is expressed on phagocytic leuko-
cytes, but to a lesser extent also on lymphocytes (17).
PACAP-38 induces mast cell degranulation and hista-
mine release, thereby contributing to edema formation
(18). In human polymorphonuclear cells it also en-
hances respiratory burst, elastase, lactoferrin, and matrix
metalloproteinase 9 release (19). Interestingly, it stimu-
lates the activity of resting macrophages, but inhibits
activated cells (16). PACAP-38 also increases the ex-
pression of several neutrophil activation markers, such
as CD11b, CD63, and CD66b, suggesting that it has a
role in neutrophil-mediated inflammatory pathways
(20). Moreover, PACAP-27 specifically induces neutro-
phil chemotaxis through FPRL1 activation and induces
phagocyte activation and Cd11b up-regulation (6). In a
model of chronic autoimmune encephalomyelitis
PACAP deficiency resulted in increased production of
proinflammatory cytokines and chemokines, but de-
creased synthesis of antiinflammatory cytokines (21).
These data demonstrate a surprisingly pleiotropic
effect of PACAP on immune cells. This might be caused
by changes in the receptor expression profile during
inflammation, as inflammatory stimuli up-regulate sev-
eral receptors (e.g., FPRL1 or VPAC1) and thereby alter
the overall effect of PACAP (22).
A possible role of PACAP in bone metabolism
has been suggested based on the presence of its recep-
tors in the bone: osteoclasts express PAC1, and bone
marrow cultures express VPAC1, VPAC2, and PAC1
(23). On desmal osteoblastic cell lines, mainly VPAC2 is
expressed, and is even up-regulated during the differen-
tiation process. However, little is known about the
expression pattern in enchondral bone tissues. Both
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PACAP-38 and VIP block osteoblast differentiation by
inhibiting alkaline phosphatase production and enhance
bone resorption by stimulating interleukin-6 production,
and thereby, osteoclast-activity (24,25). PACAP also
inhibits thyroid hormone–stimulated osteocalcin synthe-
sis in osteoblasts and decreases bone formation (26). It
has considerably greater binding and activation at
VPAC2 receptors on osteblastic cells than does VIP,
emphasizing its importance in bone proliferation (27). It
has recently been demonstrated that both PACAP-38
and VIP increase the RANKL:osteoprotegerin ratio
through activation of VPAC2 on osteoblasts, which in
turn promotes osteoclastogenesis (28). Despite the
above-mentioned reports on the effects of PACAP on
bone physiology, there is only one published study
describing a chondroprotective effect of PACAP-38
in vitro; this effect was exerted mainly by increasing
calcineurin levels (29).
In light of all of these divergent effects of PACAP
in inflammatory, vascular, immune, and pain mecha-
nisms as well as in bone turnover, we were interested in
its potential role in arthritis. To investigate this we used
a model of immune arthritis that has several well-
established similarities to RA (30,31).
MATERIALS AND METHODS
Animals and reagents. Experiments were performed
on 10–12-week-old PACAP gene–deficient mice on a CD1
background and their wild-type counterparts (PACAP/)
(32). A total of 92 animals were studied.
Because PACAP-27 and PACAP-38 are products of
the same exon, the knockout animals lack both. Animals were
bred in the Laboratory Animal House of the Department of
Pharmacology and Pharmacotherapy at the University of Pe´cs,
and were maintained in an ambient temperature of 24–25°C on
a 12-hour light/dark cycle and provided with standard rodent
chow and water ad libitum. As there were no differences in the
parameters of interest between male and female animals, both
sexes were used (except in the increasing temperature hot
plate test, in which male mice cannot be used). The studies
were approved by the Ethics Committee on Animal Research
of the University of Pe´cs according to the Ethical Code of
Animal Experiments (license no. BA 02/2000-2/2012) and
complied with the recommendations of the International As-
sociation for the Study of Pain. All reagents were obtained
from Sigma-Aldrich unless specified otherwise.
K/BxN serum–transfer arthritis model. Sera obtained
from transgene-positive (K/BxN) and -negative (BxN) mice
were pooled separately and stored at 80°C as previously
described (30,33). Arthritis was induced by intraperitoneal
injection of arthritogenic (K/BxN) or control (BxN) serum on
day 0. The amount administered was 150 l for mice used in
functional tests, as debilitating joint dysfunction produces gait
abnormalities and limits functional nociception measure-
ments. For in vivo imaging and histologic studies a single dose
of 300 l was used, to produce massive joint inflammation
and cellular infiltration. For assessment of structural damage,
2 additional 150-l booster injections were administered on
days 10 and 20 to maintain longer-lasting inflammation and
mimic the late, degenerative phase.
Evaluation of disease severity and hind paw edema.
Arthritis severity, hyperemia, and paw volume were assessed
daily by evaluation for edema and hyperemia (2 classic signs of
inflammation) (33) and measurement of hind limb edema by
plethysmometry (Ugo Basile) (34). The results were scored on
a scale of 0–10 (0–0.5  intact limb; 10  most severe
changes).
In vivo fluorescence imaging of vascular leakage. In-
docyanine green (ICG) is a Food and Drug Administration–
approved fluorescent cyanine near-infrared dye that, upon
intravenous injection, rapidly binds to plasma proteins and
remains in the healthy vasculature until excreted by the liver.
It is suitable for use in imaging inflammatory hypervascular-
ization and capillary leakage in arthritis both in preclinical
models (35) and in patients with RA (36). To overcome its
rapid clearance and stability problems when in aqueous solu-
tions, non-ionic emulsifiers are used to encapsulate and stabi-
lize ICG in micelles (37) and increase its plasma elimination
half-life (38). Therefore, ICG (0.5 mg/kg) dissolved in a 5%
(weight/volume) aqueous solution of Kolliphor HS 15, a
macrogol-based surfactant (37), was injected intravenously
into mice that had been anesthetized by intraperitoneal admin-
istration of 50 mg/kg sodium pentobarbital. Imaging (IVIS
Lumina II optical imager; PerkinElmer) was performed 5, 10,
20, 30, and 60 minutes postinjection on days 0, 2, and 5, since
vascular leakage is an early sign in this arthritis model. Imaging
parameters were as follows: auto acquisition time (F-stop) 1,
Binning 2, excitation 745 nm, emission filter 800 nm. Data
were analyzed using Living Image software (PerkinElmer).
Standardized regions of interest (ROIs) were drawn around
the ankle joints. A calibrated unit of fluorescence, the radiant
efficiency ([photons/second/cm2/steradian]/[W/cm2]) origi-
nating from the ROIs was used for further analysis.
Measurements of mechano- and thermonociception.
The mechanical hyperalgesia of the hind paw was measured by
dynamic plantar esthesiometry (Ugo Basile). Mechanonoci-
ceptive threshold was expressed in grams (34). The thermo-
nociceptive threshold was determined using an increasing-
temperature hot plate (IITC Life Sciences) heated increasingly
from 30°C until the animal either exhibited nocifensive re-
sponses (lifting, shaking, or licking either paw) or the preset
maximum (53°C) was attained (10). One conditioning and 2
control measurements were performed before arthritis induc-
tion.
Assessment of motor performance and joint function.
To determine joint function and grasping ability, mice were
placed on a horizontal wire grid, which was then turned over
and maintained in this position for 20 seconds or until the
animal fell. This is a simple but reliable method for functional
analysis in this model (33). Potential impairment of locomotor
coordination related to joint rigidity and consequent dysfunc-
tion were also studied using an accelerating rotarod (Ugo
Basile) and expressed as the time spent on the wheel (14).
Arthritis induction was preceded by 3 control measurements.
In vivo bioluminescence imaging of myeloperoxidase
and NADPH oxidase activity. Luminol (5-amino-2,3-dihydro-
1,4-phthalazinedione) and lucigenin (bis-N-methylacridinium
nitrate) are used to detect reactive oxygen species (ROS).
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Figure 1. Edema, clinical severity, and inflammatory vascular leakage in PACAP/ (wild-type) and PACAP/ mice in which arthritis was not induced
(controls administered normal serum) or in which arthritis was induced by administration of K/BxN mouse serum. A and B, Plethysmometric determination
of hind paw volumes (A) and clinical scores of disease severity (B) (n  812 per group). C, Representative images of indocyanine green (ICG)
fluorescence in the ankle joints, as an indicator of vascular permeability and leakage. Images were obtained 5 minutes and 60 minutes after intravenous
injection of ICG (0.5 mg/kg). D, ICG fluorescence intensity ([photons/second/cm2/steradian]/[W/cm2] [p/s/W/cm2]) in the ankle joints 2 days and 5 days
after induction of arthritis (n  56 per group). Values in A, B, and D are the mean  SEM.   P  0.05;   P  0.01;   P  0.001 versus the
respective control group. # P 0.05; ## P 0.01; ### P 0.001 versus the K/BxN serumtreated wild-type group. Color figure can be viewed
in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38772/abstract.
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Luminol bioluminescence detects mainly to neutrophil myelo-
peroxidase (MPO) activity, and lucigenin bioluminescence
detects NADPH oxidase activity and extracellular superoxide
production of macrophages (39,40). Na-luminol and lucigenin
(Santa Cruz Biotechnology) were dissolved in phosphate buff-
ered saline to form 20-mg/ml and 2.5-mg/ml stock solutions,
respectively. Anesthetized mice were injected intraperitoneally
with 150 mg/kg luminol (days 0, 1, 2, and 4) or 25 mg/kg
lucigenin (days 0, 2, 6, and 10). Bioluminescence imaging was
performed 10 minutes postinjection using an IVIS Lumina II.
Acquisition time was 60 seconds, F-stop 1, Binning 8. Data
were analyzed and ROIs were applied; luminescence was
expressed as total radiance (photons/second/cm2/steradian)
within the ROIs.
In vivo investigation of metabolic activity by positron
emission tomography/magnetic resonance imaging (PET/
MRI). In vivo PET/MRI scans were obtained on day 4 using
2-18F-2-fluoro-2-deoxy-D-glucose (18F-FDG; 4 MBq per ani-
mal administered intravenously) and nanoScan PET/MRI
(Mediso). The glucose analog 18F-FDG exhibits increased
uptake kinetics in high-glucose–using cells of inflamed tissue.
18F-FDG accumulation adequately reflects inflammatory mac-
rophage activity in acute arthritis, whereas it is less sensitive
to neutrophils or T cells. In chronic arthritis, fibroblast prolif-
eration and pannus formation are the main causes of radio-
isotope accumulation (41). MR images (gradient-echo–
external averaging sequence) using a MultiCell imaging bed
(Mediso) were overlaid on the PET scans. PET images were
reconstructed with a Nucline Tera-Tomo PET algorithm
(ordered-subsets expectation-maximization 3-dimensional re-
construction; Mediso) using 300-m voxels. The standardized
uptake values maximum (SUVmax) of
18F-FDG, i.e., the max-
imum values of the tissue radioactivity concentration divided
by (injected activity/body mass) in the ROIs, were calculated in
the ankle joints.
In vivo micro–computed tomography (micro-CT) ana-
lysis of the tibiotarsal joint and bone structures. Micro-CT
imaging was performed on the same mice at every time point
to minimize interindividual differences. The right ankles were
repeatedly scanned (days 0, 7, 14, and 28) using the same
settings and 17.5-m voxel size, with a SkyScan 1176 micro-CT
(Bruker). After reconstruction of the scans, bone structural
changes were analyzed using CT Analyser software. Standard-
ized ROIs were drawn around the periarticular region of the
tibia and fibula, as well as the tibiotarsal and tarsometatarsal
joints. In these ROIs bone volume (BV; m3) and bone
surface (BS; m2) were calculated and expressed as the
percentage of the standardized total volume (TV) of the ROI
(% BV and BS density).
Histologic evaluation of joint inflammation. Mice
were killed on day 4 or day 28 to investigate acute and chronic
alterations. They were transcardially perfused with 4% buff-
ered paraformaldehyde, and ankle joints were fixed in the
same buffer, decalcified and dehydrated, embedded in paraf-
fin, sectioned (3–4 m), and stained with Safranin O. The
slides were evaluated semiquantitatively by a pathologist under
blinded conditions. Synovial cell proliferation and mono-
nuclear cell infiltration were scored from 0 (normal) to 3
(maximal severity) (34).
Statistical analysis. Results are expressed as the
mean  SEM. Statistical evaluation was performed using
GraphPad Prism. Distribution of the data was tested by
D’Agostino-Pearson or Shapiro-Wilk, test depending on the
number of values. The significance of ICG imaging, clinical
scoring, and plethysmometry results was evaluated by
Kruskal-Wallis test, and functional results by repeated-
measures analysis of variance (ANOVA). Wire grid perfor-
mance was evaluated by log rank test, micro-CT results by
two-way ANOVA, in vivo bioluminescence and PET imaging
results by Student’s t-test, and histopathologic scores by Mann-
Whitney U test. P values less than 0.05 were considered
significant.
RESULTS
Reduced joint inflammation and edema in
PACAP/mice. After induction of arthritis in wild-type
mice by administration of 150 l arthritogenic serum,
substantial hind paw edema developed, which peaked on
day 3 at 40% and gradually decreased thereafter. In
PACAP/ animals, edema was present to a signifi-
cantly lesser extent but the kinetics pattern was similar,
with the maximum (20%) reached on day 5 (Figure 1A).
Semiquantitative clinical scoring of edema and hyper-
emia showed similar results, but peak scores occurred on
day 34 in wild-type mice and on day 5 in PACAP/
mice. Arthritis severity scores were, however, signifi-
cantly lower in the PACAP-deficient mice (Figure 1B).
Decreased inflammatory hyperemia and vascu-
lar leakage in PACAP/ mice. Before treatment, ICG
fluorescence was similarly low in the ankle joints of
PACAP/ and PACAP/ mice, demonstrating negli-
gible extravasation of the dye. Two days after induc-
tion of arthritis, the accumulation and fluorescence of
ICG were notably increased in the ankle joints of
wild-type mice both immediately after injection and 1
hour later, indicating hyperemia and plasma leakage
(80% increase at 5 minutes, 170% at 1 hour postinjec-
tion compared to initial control data). In contrast, in
PACAP-deficient animals the increase was significantly
smaller (25% at 5 minutes, 65% after 1 hour). By day 5,
ICG fluorescence increased even further in both wild-
type mice (120% at 5 minutes, 320% after 1 hour) and
PACAP/ mice (60% and 130%, respectively) (Figures
1C and D).
Diminished mechanical hyperalgesia in PACAP/
mice. There was no difference in mechano- or ther-
monociceptive thresholds between control PACAP/
and control PACAP/ mice. In wild-type mice with
arthritis, the mechanocociceptive threshold was de-
creased by 15–20% by day 5 after disease induction, but
was normalized by day 9. Mechanical hyperalgesia did
not develop in either arthritic PACAP/ mice or
normal serum–treated control PACAP/ mice (Fig-
ure 2A). Arthritis did not result in a significant change
in thermonociceptive thresholds in any of the groups
(Figure 2B).
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Retained grasping ability of PACAP/ mice.
The horizontal wire grid test revealed an abrupt de-
crease in grasping ability in wild-type mice; by day 4,
only 30% of the mice could stay on the grid for 20
seconds. In contrast, 75–80% of the PACAP/ animals
could stay on the grid for this duration (Figure 2C).
Motor performance on the rotarod gradually improved
in all groups during the experimental period, demon-
strating learning. The improvement was significant in
the PACAP/ group but not in the PACAP-deficent
group (Figure 2D).
Decreased neutrophil MPO activity in the ankle
joints of PACAP/ mice in the early phase of arthritis
and increased activity in the later phase. Luminol
bioluminescence imaging showing MPO activity in the
inflamed joints of PACAP/ mice peaked in the initial
phase of arthritis, reaching a maximum on day 1 and
gradually decreasing thereafter. The initially diffuse
activity in the hind paws rapidly declined and was
concentrated in the tibiotarsal joints by day 4. In con-
trast, in PACAP/ mice early MPO activity was signif-
icantly lower, but by day 4 it became significantly greater
in the ankles (Figures 3A and B).
Lack of inflammatory superoxide production in
PACAP/ mice. In PACAP/ mice, lucigenin bio-
luminescence, indicating the presence of extracellular
superoxides, steadily increased, reaching a maximum
on day 6. Its elevation occurred more slowly compared
to that observed with luminol bioluminescence imag-
ing, highlighting the differences between these markers.
Superoxide generation in PACAP/ mice remained
similar to baseline and was significantly lower than that
observed in wild-type mice (Figures 3C and D).
Increased and accelerated periarticular osteo-
phyte formation in PACAP/ mice. CT scanning re-
vealed differences in the bone architecture of
PACAP/mice even in the absence of arthritis. BV/TV
in these mice was consistently increased in both the
talocrural and distal periarticular regions of the tibia and
fibula, although these increases were not significant.
Bone surface density in these animals, expressed as
BS/TV, was similar to that in wild-type mice. Arthritis
Figure 2. Evaluation of nociceptive changes and motor impairment. A, Mechanonociceptive threshold in the hind paw (n  8–12 per group). B,
Thermonociceptive threshold measured using an increasing-temperature hot plate (n 4–6 per group). C, Kaplan-Meier curve of the ability to hold
onto a wire grid for 20 seconds (n  8–12 per group). Animals were habituated in 3 control sessions prior to the induction of arthritis. D, Motor
performance on an accelerating rotarod during 3 consecutive control measurements and following the induction of arthritis (n  4–6 per group).
Values in A, B, and D are the mean  SEM.   P  0.01;   P  0.001 versus the respective control group. #  P  0.05; ##  P  0.01;
###  P  0.001 versus the K/BxN serum–treated wild-type group.
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Figure 3. Bioluminescence imaging of neutrophil-derived myeloperoxidase activity and macrophage-derived superoxide activity. A and B,
Representative images of luminol activity obtained 10 minutes after intraperitoneal injection of Na-luminol (150 mg/kg) (A) and quantification of
luminescence in diseased ankle joints (B). C and D, Representative images of lucigenin-based superoxide detection (C) and quantification of
luminescence in diseased ankle joints 10 minutes after intraperitoneal injection of lucigenin (25 mg/kg) (D). Values in B and D are the mean SEM
photons/second (p/s) (n  46 per group).   P  0.05 versus control PACAP/ mice; ##  P  0.01. Color figure can be viewed in the online
issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38772/abstract.
Figure 4. Micro–computed tomography (micro-CT) analysis of structural changes in bone architecture. A and B, Representative 3-dimensional
micro-CT reconstruction and histologic analysis of the tibiotarsal joints (A) and the periarticular region of the tibia and fibula (B). In the 4 images
on the far right, bone spur formation (asterisks) can be seen in the 3-dimensional reconstructions (magnified views of the boxed areas), in an
axial CT slice, and in a photomicrograph of the periarticular region of the tibia and fibula of a PACAP/ mouse. Original magnification  100.
C and D, Changes in bone volume/total volume (BV/TV) and in bone surface (BS)/TV over time in the vicinity of the tibiotarsal joint (C)
and the periarticular region of the tibia (D). Values are the mean  SEM (n  6 per group).   P  0.0001 versus nonarthritic control
PACAP/ mice. #  P  0.05; ##  P  0.01; ####  P  0.0001. Color figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/doi/10.1002/art.38772/abstract.
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did not substantially alter bone characteristics in
PACAP/ mice. In contrast, in PACAP/ mice it
induced extensive, progressive osteophyte formation in
the periarticular region of the tibia and fibula, which was
apparent by day 14 (Figures 4A and B). These bone
spurs had become compact, dense bone by day 28,
leading to a prominent, significant increase in bone
mass, even reaching 70% extra bone in some mice
compared to controls (Figures 4C and D).
Decreased metabolic activity in the diseased
ankle joints of PACAP/ mice. In the inflamed tibio-
tarsal joints of wild-type mice, metabolism was signifi-
cantly increased on day 4, as shown by the elevated
SUVmax values. In contrast, metabolism in the joints
of arthritic PACAP-deficient animals did not differ
from that observed in nonarthritic controls (Figures 5A
and B).
Increased synovial hyperplasia in PACAP/
mice. Histopathologic analysis of the joints revealed no
difference between control serum–treated PACAP/
and PACAP/ mice. In both groups the tibiotarsal
joint, synovium, and periarticular connective tissue ap-
peared normal (Figures 6AC). Four days after arthritis
induction there were prominent changes in the
PACAP/ group, i.e., an irregular cartilagebone bor-
der, enlarged synovium infiltrated with inflammatory
cells, and massive infiltration of immune cells into the
periarticular connective tissue with formation of mono-
nuclear cell aggregates (Figure 6A–C). Similar changes
were observed in the PACAP/mice, and the degree of
synovial hyperplasia was greater than that in the wild-
type mice whereas the degree of mononuclear cell
infiltration was comparable (Figure 6D). By day 28 these
acute inflammatory signs had decreased, but the carti-
lagebone border became more irregular and the car-
tilage width was notably reduced in both groups (Figure
6A). The previously infiltrated synovial lining and con-
nective tissue showed prominent collagen deposition,
indicating the chronic stage of inflammation. The patho-
logic spurs in PACAP/ mice demonstrated on the
micro-CT scans were also identified by their irregularity,
distinct staining, and notable vascularization seen on
histologic analysis (Figure 6D). These features were
absent in wild-type mice.
DISCUSSION
The primary and most important result of our
study is the finding, for the first time, of evidence of a
surprisingly pleiotropic effect of PACAP on different
characteristics in a multifactorial transgenic disease
model of RA. K/BxN mice display a spontaneous
and progressive polyarthritis, with persistence of high-
titer autoantibodies, mainly anti–glucose-6-phosphate
isomerase, in the serum (30,31). This serum induces a
similar, but transient, arthritis, mainly through inflam-
matory cytokine production, complement activation,
neutrophil activation, and mast cell degranulation.
In this model, which has translational signifi-
cance, PACAP deficiency decreases vasodilation,
plasma leakage, acute inflammatory cell accumulation,
hyperalgesia, joint dysfunction, metabolic activity, and
ROS generation, while facilitating later neutrophil ac-
tivity, synovial cell proliferation, and pathologic bone
formation. The second important message derived from
our study, from a methodologic and translational stand-
Figure 5. Positron emission tomography/magnetic resonance imaging (PET/MRI) of inflammatory metabolic burst. A, Representative 2-18F-2-
fluoro-2-deoxy-D-glucose (18F-FDG; 4 MBq per animal) PET/MRI multimodal reconstruction images obtained 4 days after induction of arthritis.
Areas with increased glucose uptake correspond to the intracapsular space containing tendons and joint capsule internal surface, as identified by
both PET and MR signals. B, Quantitative evaluation of the standardized uptake value maximum (SUVmax) of
18F-FDG in the ankle joints. Values
are the mean  SEM (n  3 per group).   P  0.01 versus nonarthritic control PACAP/ mice. Color figure can be viewed in the online issue,
which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38772/abstract.
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point, is that the K/BxN serum–transfer model is ap-
propriate for investigating several early and late charac-
teristics of RA using in vivo noninvasive imaging
modalities. We adopted and modified in vivo functional
and optical imaging techniques, as well as observational
longitudinal experimental paradigms that help to iden-
tify key pathophysiologic mechanisms in inflammatory
and degenerative joint diseases.
The potent edema-forming and acute inflamma-
tory actions of PACAP can be explained by its well-
established vasoactive effects (12,42). Our in vivo plasma
extravasation imaging results provide deeper insight into
the core mechanisms responsible for this phenomenon
and validate the functional data. Both VPAC and PAC1
receptors are likely to be involved in the vascular effects
of PACAP: since nitric oxide might act as an agonist at
the VPAC2 receptor, its level of synthesis can interact
with VPAC-mediated pathways in vasodilation (43), and
PAC1 receptor is of key importance in the induction of
plasma leakage (13,44).
The absence of arthritic hyperalgesia in PACAP/
mice correlates well with previous results reported by
our group and others, demonstrating that PACAP-38
has a pronociceptive role in peripheral pain conditions,
in which sensitization mainly occurs in the spinal dorsal
horn (8–10,14,45,46). This suggests the importance of
PAC1 receptor activation in the central nervous system
(CNS), since intrathecal administration of a PAC1 re-
ceptor antagonist had an antinociceptive effect in osteo-
arthritis (47).
The almost-normal grasping ability of arthritic
PACAP/ mice is likely due to milder joint swelling
and pain. We did not find disease-related alterations in
motor performance on the rotarod wheel in our exper-
iments, similar to previously reported findings in a
model of peripheral neuropathy (14). This can be ex-
plained by the fact that this test mainly reflects motor
coordination related to CNS processes, and inflamma-
tion of the small joints in this model does not influence
performance.
We observed an interesting 2-phase pattern re-
garding the effect of PACAP deficiency on MPO activity
during arthritis: in the early phase neutrophil activity is
clearly and notably decreased in PACAP/ mice, cor-
relates well with our functional results but virtually
contradicts the traditional view about the inhibitory
effects of PACAP on immune cells (16). The explana-
tions are likely to be 1) increased migration of immune
cells into the inflamed tissue mainly due to the PACAP-
38–driven capillary permeability increase through PAC1
receptor activation (12,18,44), and 2) the key importance
of PACAP-27 in facilitating neutrophil chemotaxis and
migration during the initial phase of the inflammation
(6). Thus, we can conclude that these proinflammatory
Figure 6. A–C, Representative photomicrographs of the ankle joints
of control PACAP/ and PACAP/ mice and PACAP/ and
PACAP/ mice after arthritis induction. Images of the tibiotarsal
joints including cartilage lining (A), the synovium (B), and periarticular
soft tissue (C) are shown. Blue staining in the day 28 images in B and
C represents collagen deposition. Original magnification 100 in A;
200 in B and C. D, Left, Semiquantitative histopathologic scores of
synovial hyperplasia and mononuclear cell infiltration on day 4. Values
are the mean  SEM (n  4–6 per group). Right, Representative
photomicrograph of a bone spur observed in a PACAP/ mouse on
day 28. Asterisk indicates the tibia. Arrows show irregular, cell-rich
new bone (a) and a vessel entering the affected area (b).
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effects of PACAP lead to more rapid formation of the
inflammatory microenvironment (19,20).
In contrast, the increased luminol biolumines-
cence in the later phase suggests that PACAP inhibits
neutrophil activity by suppressing proinflammatory cy-
tokine production and increasing the expression of
antiinflammatory mediators (16,21). This is consistent
with earlier data showing that exogenous administration
of PACAP reduces disease severity and inflammatory
enzyme production in mice with collagen-induced arthri-
tis (48). However, it is important to note that in the
collagen-induced arthritis model there are profound T
and B cell responses, whereas K/BxN serum–transfer
arthritis depends mainly on myeloid lineages and devel-
ops similarly if T and B cells are absent (33). In our
model the maximal inflammatory cell activity occurs on
day 1 as shown by luminol bioluminescence, which is
surprising since this is a very early phase of the disease,
when functional changes are minimal. This suggests the
importance of further studying this early period to
elucidate the mechanisms that precede edema formation
and functional loss.
The significantly lower level of extracellular ROS
production in gene-deficient mice suggests that PACAP
stimulates macrophage activity in arthritis and has dis-
tinct proinflammatory effects on phagocytes. The lack of
increased inflammatory metabolic activity in the joints
of PACAP/ mice shown by 18F-FDG–PET can be
attributed to decreased macrophage activity (41).
The effects of PACAP on bone/cartilage metab-
olism and turnover have not previously been investi-
gated in vivo under either normal or arthritic conditions.
Our study provides substantial new evidence regarding
its crucial role in bone pathophysiology. We dem-
ostrated that PACAP is a key regulator of bone turn-
over, particularly in inflammation. There are few, exclu-
sively in vitro, data describing the ability of PACAP-38
to inhibit osteoblast precursors (24,25) and to diminish
osteoclastogenesis (28). Taken together, the results of
those studies and our present findings indicate that
PACAP plays a crucial role in chondro- and osteogene-
sis by regulating bone formation and inhibiting patho-
logic osteophyte growth. Our finding of osteophyte
formation in the late phase of disease indicates that this
model has translational relevance regarding the degen-
erative complications of RA.
Synovial hyperplasia is a characteristic and widely
investigated feature of RA. It is due to the formation of
disinhibited fibroblast-like synoviocytes (FLS) that ex-
press NF-B and secrete several inflammatory cytokines
and adhesion molecules (interleukin-6, CCL-2, vascular
cell adhesion molecule 1, intercellular adhesion mole-
cule 1). Consequently, there is an influx and accumula-
tion of inflammatory cells, which produce cytokines,
chemokines, and proteases (matrix metalloproteinases,
cathepsins, etc.), leading to cartilage and bone destruc-
tion. It was recently demonstrated that in the K/BxN
model, FLS develop and exhibit behavior similar to that
in human RA (49). This, taken together with the in-
creased synovial hyperplasia in PACAP-deficient mice,
suggests that PACAP might reduce FLS formation and
exert a protective effect in chronic arthritis. This is also
supported by the finding of pathologic bone neoforma-
tion in PACAP/ mice, which can be at least partially
attributed to FLS-derived mediators.
The general limitations of experiments with
knockout animals are that global gene deficiency can
lead to potential phenotypic alterations during prenatal
development and induce compensatory mechanisms.
The possible effects of the flanking genes should also be
taken into consideration. Discrepancies have been ob-
served when comparing preclinical results obtained in
knockout animals and clinical trial outcomes; for exam-
ple, interferon- deficiency in mice was shown to induce
arthritis, but clinical trials with interferon- resulted in
only slight improvement in patients with RA (50).
In conclusion, PACAP deficiency has complex
consequences with regard to several mechanisms re-
lated to RA. It decreases hyperemia, plasma leakage,
and edema (most likely due to the lack of the potent
vasodilating effect of PACAP) as well as functional
impairment, and abolishes pain and sensitization. This in
turn moderates the early migration of immune cells into
the synovium and reduces metabolic activity. PACAP
deficiency decreases early accumulation of neutrophils
by slowing their extravasation from the vessels, but
facilitates their function in the later phase. In addition, it
decreases macrophage activity and ROS production and
promotes inflammation-induced pathologic bone neo-
formation. We have provided experimental evidence of
the important and complex regulatory function of
PACAP. Identification of its targets and precise mech-
anisms might open future avenues for development of
therapies aimed at both acute RA symptoms and chronic
structural changes.
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